search this site
- home
- highlights
- sinclair at a glance
- growing our operations worldwide
- products:oral health
- products:dermatology
- chairman´s statement
- business review:operational
- business review:financial
- board of directors
- senior management
- directors´ report
- corporate governance report
- directors´ remuneration report
- independent auditors´ report
- consolidated income statement
- balance sheets
- statements of changes in shareholders´ equity
- cash flow statements
- notes to the financial statements
- corporate advisors
Cash Flow Statements
for the year ended 30 June 2008
Group |
Company |
||||||
2008 |
2007 |
2008 |
2007 |
||||
Note |
£'000 |
£'000 |
£'000 |
£'000 |
|||
| Cash flows from operating activities | |||||||
| Net cash outflow operations | (3,250) |
(1,185) |
(4,687) |
(2,787) |
|||
| Interest paid | (281) |
(68) |
(135) |
(36) |
|||
| Interest paid on finance leases | (41) |
(43) |
— |
— |
|||
| Taxation paid | (124) |
(303) |
— |
— |
|||
| Net cash used in operating activities | (3,696) |
(1,599) |
(4,822) |
(2,823) |
|||
| Investing activities | |||||||
| Interest received | 67 |
115 |
1,472 |
48 |
|||
| Purchases of property, plant and equipment | (166) |
(444) |
— |
— |
|||
| Proceeds from sale of property, plant and equipment | 47 |
74 |
— |
— |
|||
| Purcahse of intangible assets | (3,907) |
(952) |
— |
— |
|||
| Proceeds from sale of product rights | — |
1,315 |
— |
— |
|||
| Repayment of intra-group loans | — |
— |
1,419 |
539 |
|||
| Payment of contingent consideration regarding Groupe CS Dermatologie | (223) |
— |
(223) |
— |
|||
| Acquisition of subsidiary undertaking, net cash aqcuired | (14) |
(612) |
(14) |
(1,324) |
|||
| Net cash in investing activities | (4,196) |
(504) |
2,654 |
(737) |
|||
| Financing activities | |||||||
| Repayments of obligations under finance leases | (156) |
(103) |
— |
— |
|||
| Proceeds from borrowings | 5,370 |
506 |
1,780 |
510 |
|||
| Repayments from borrowings | (653) |
(184) |
(393) |
(25) |
|||
| Proceeds from issue of share capital | — |
88 |
— |
88 |
|||
| Net cash from financing activities | 4,561 |
307 |
1,387 |
573 |
|||
| Net decrease in cash, cash equivalents and bank overdrafts | (3,331) |
(1,796) |
(781) |
(2,987) |
|||
| Cas, cash equivalents and bank overdrafts at 1 July | 2,604 |
4,470 |
398 |
3,385 |
|||
| Exchange gains/(losses) on cash and bank overdrafts | 373 |
(70) |
— |
— |
|||
| Cash, cash equivalents and bank overdrafts at end of year | (354) |
2,604 |
(383) |
398 |
|||
| Cash, cash equivalents and bank overdrafts includes: | |||||||
| Cash and cash equivalents | 1,052 |
2,791 |
21 |
398 |
|||
| Bank overdrafts | (1,406) |
(187) |
(404) |
— |
|||
| Cash, cash equivalentsand bank overdrafts | (354) |
2,604 |
(383) |
398 |
|||